Unity Biotechnology Company
Unity Biotechnology finds solutions against age-related diseases, such as vision loss and cognitive decline, cause considerable economic, personal, and societal burdens for individuals, their families, and broader communities. By targeting age-related diseases, we believe that UNITY can treat these diseases, as well as contain healthcare costs and lessen the emotional and societal burden that comes with an aging population.
Investors
Connections from
Founded Date:
2009
Total Funding:
210.6M
Investor Type:
IPO
Employee Number:
51-100
Funding Status:
Series C
Number Of Exists:
51-100
Technology:
Geroscience
Last Funding Type:
Series C
Investors Number:
23
Last Funding Date:
Mar 19, 2018
Industry:
Drug Development, Gene therapy
Headquarters:
Brisbane, California, United States
Estimated Revenue:
$10M to $50M